Cannabis Watch: GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients

175

Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-based treatment for multiple sclerosis spasticity can now proceed. Volume of 2.14 million shares traded was 5.5 times the 65-day average of 385,930. GW Pharma GWPH, +21.18%  is the first company to win U.S. .en.

Ga naar Bron